Commentary: "Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease" by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519

Harma Alma; Corina de Jong; Janwillem Kocks; Thys van der Molen

doi:10.3389/fphar.2020.00827

Commentary: "Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease" by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519

Harma Alma^*
, Corina de Jong
, Janwillem Kocks
, Thys van der Molen

^*Corresponding author for this work

Groningen Research Institute for Asthma and COPD (GRIAC)

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

139 Downloads (Pure)

Original language	English
Article number	827
Number of pages	3
Journal	Frontiers in Pharmacology
Volume	11
DOIs	https://doi.org/10.3389/fphar.2020.00827
Publication status	Published - 2-Jun-2020

Access to Document

10.3389/fphar.2020.00827Licence: CC BY

Commentary “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary DiseaseFinal publisher's version, 409 KBLicence: CC BY

Handle.net

Persistent link

Cite this

Alma, H., de Jong, C., Kocks, J., & van der Molen, T. (2020). Commentary: "Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease" by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519. Frontiers in Pharmacology, 11, Article 827. https://doi.org/10.3389/fphar.2020.00827

@article{a485bc804a6848f69d2662c822d60560,

title = "Commentary: {"}Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease{"} by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519",

author = "Harma Alma and \{de Jong\}, Corina and Janwillem Kocks and \{van der Molen\}, Thys",

year = "2020",

month = jun,

day = "2",

doi = "10.3389/fphar.2020.00827",

language = "English",

volume = "11",

journal = "Frontiers in Pharmacology",

issn = "1663-9812",

publisher = "Frontiers Media SA",

}

Alma, H , de Jong, C , Kocks, J & van der Molen, T 2020, 'Commentary: "Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease" by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519', Frontiers in Pharmacology, vol. 11, 827. https://doi.org/10.3389/fphar.2020.00827

Commentary: "Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease" by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519. / Alma, Harma ; de Jong, Corina ; Kocks, Janwillem et al.
In: Frontiers in Pharmacology, Vol. 11, 827, 02.06.2020.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Commentary: "Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease" by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519

AU - Alma, Harma

AU - de Jong, Corina

AU - Kocks, Janwillem

AU - van der Molen, Thys

PY - 2020/6/2

Y1 - 2020/6/2

U2 - 10.3389/fphar.2020.00827

DO - 10.3389/fphar.2020.00827

M3 - Comment/Letter to the editor

C2 - 32581793

SN - 1663-9812

VL - 11

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

M1 - 827

ER -

Alma H , de Jong C , Kocks J, van der Molen T. Commentary: "Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease" by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519. Frontiers in Pharmacology. 2020 Jun 2;11:827. doi: 10.3389/fphar.2020.00827